A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä

Maternal gluten, cereal, and dietary fiber intake during pregnancy and lactation and the risk of islet autoimmunity and type 1 diabetes in the child




TekijätHakola Leena, Lund-Blix Nicolai A., Takkinen Hanna-Mari, Tapanainen Heli, Niinistö Sari, Korhonen Tuuli E., Stene Lars C., Hyöty Heikki, Toppari Jorma, Ilonen Jorma, Knip Mikael, Veijola Riitta, Virtanen Suvi M.; HEDIMED Investigator group

KustantajaElsevier

Julkaisuvuosi2024

JournalClinical Nutrition ESPEN

Tietokannassa oleva lehden nimiClinical Nutrition ESPEN

Vuosikerta62

Aloitussivu22

Lopetussivu27

ISSN2405-4577

eISSN2405-4577

DOIhttps://doi.org/10.1016/j.clnesp.2024.05.001

Verkko-osoitehttps://doi.org/10.1016/j.clnesp.2024.05.001

Rinnakkaistallenteen osoitehttps://research.utu.fi/converis/portal/detail/Publication/404698768


Tiivistelmä

Background & aims Maternal gluten intake in relation to child's risk of type 1 diabetes has been studied in few prospective studies considering the diet during pregnancy but none during lactation. Our aim was to study whether gluten, cereals, or dietary fiber in maternal diet during pregnancy and lactation is associated with the risk of islet autoimmunity or type 1 diabetes in the offspring.

Methods We included 4943 children with genetic susceptibility to type 1 diabetes from the Finnish Type 1 Diabetes Prediction and Prevention (DIPP) Study, born between 1996 and 2004. Maternal intake of gluten, different types of cereals, and dietary fiber were derived from a semi-quantitative validated food frequency questionnaire covering the eighth month of pregnancy and the third month of lactation. Children were monitored for islet autoantibodies up to age of 15 years and type 1 diabetes until year 2017. Risk of islet autoimmunity and clinical type 1 diabetes were estimated using Cox regression model, adjusted for energy intake, child's sex, HLA genotype, and familial diabetes.

Results Altogether 312 children (6.4%) developed islet autoimmunity at median age of 3.5 (IQR 1.7, 6.6) years and 178 children (3.6%) developed type 1 diabetes at median age of 7.1 (IQR 4.3, 10.6) years. Gluten intake during pregnancy was not associated with islet autoimmunity (HR 0.96; 95% CI 0.68, 1.35), per 1 g/MJ increase in intake nor type 1 diabetes (HR 0.96; 95% CI 0.62, 1.50) in the offspring. Higher barley consumption during lactation was associated with increased risk of type 1 diabetes (HR 3.25; 95% CI 1.21, 8.70) per 1 g/MJ increase in intake. Maternal intake of other cereals or dietary fiber was not associated with the offspring outcomes.

Conclusions We observed no association between maternal intake of gluten, most consumed cereals, or dietary fiber during pregnancy or lactation and the risk of islet autoimmunity or type 1 diabetes in children from a high-risk population.


Ladattava julkaisu

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail. Please cite the original version.




Julkaisussa olevat rahoitustiedot
Supported by the Research Council of Finland (grants 63 672, 68 292, 79 685, 79 686, 80 846, 114 666, 126 813, 129 492, 139 391, 201 988, 210 632, 250 114, 276 475, 308 066, 339 922); European Foundation for the Study of Diabetes award supported by EFSD/JDRF/Lilly; the Diabetes Research Foundation; the Juho Vainio Foundation; Competitive Research Funding of the Turku and Oulu University Hospitals; the Competitive State Research Financing of the Expert Responsibility area of Tampere University Hospital (grants 9E082, 9F089, 9G087, 9H092, 9J147, 9K149, 9L042, 9L117, 9M036, 9M114, 9N086, 9P057, 9R055, 9S074, 9T072, 9U065, 9V072, 9X062, 9AA084, 9AB083); the Juvenile Diabetes Research Foundation (grants 4-1998-274, 4-1999-731, 4-2001-435, 1-SRA-2016-342-M-R, 1-SRA-2019-732-M-B, and 3-SRA-2020-955-S-B); the Novo Nordisk Foundation; the European Union Biomed 2 Program (BMH4-CT98-3314). This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 874864 HEDIMED.


Last updated on 2025-27-01 at 19:40